Archives Organizers
Lifeasible
Lifeasible has launched its 2026 Back-to-School Sale, offering 17% off all products and 12% off all services from September 1 through September 30, 2026. The month-long promotion brings product discounts and customized research services together for laboratories preparing new experiments and research projects during the new academic season. “As researchers begin new projects or continue ongoing studies, their needs can vary from experimental materials to specialized research support,” said Isla, one of the representative speakers from Lifeasible. “By including both products and services in this campaign, we hope to give researchers more flexibility when planning their work and selecting the resources they need.” The product promotion covers Lifeasible’s research portfolio, including reagents, kits, biochemicals, competent cells, and other research materials. Featured products include Agrobacterium competent cells and insecticidal proteins, along with other resources relevant to plant and agricultural research. The selection of products is intended to accommodate different laboratory requirements. For researchers working on plant transformation or genetic engineering projects, competent cells can form part of gene delivery workflows, while insecticidal proteins can be used in research related to crop protection and pest management. The promotion also includes Lifeasible’s custom services, with 12% off all services during the campaign period. Featured services cover plant transformation, plant genetic engineering, exosome services, and metabolomics analysis. The available support spans several stages of research. Plant transformation and genetic engineering services can be used for projects involving gene integration, expression, or targeted genetic modification. Other services provide support for downstream research and analysis, including studies related to gene function, gene expression, plant physiology, and plant biochemistry. For projects involving multiple experimental stages, the combination of products and customized services can provide researchers with different options as their work develops. A laboratory may require research materials for an initial experiment and later seek specialized services for genetic engineering or analytical work, depending on the objectives of the project. The Back-to-School Sale runs from September 1 through September 30, 2026. Customers can use the promotional code 2026BTS in the “Project Description” field when making an inquiry or purchase to receive the applicable discount. The September campaign gives researchers an opportunity to plan product purchases and customized research support during the promotional period, with discounts available across Lifeasible’s products and services through September 30. For more information, please visit https://www.lifeasible.com/back-to-school-sale-2026/.
Creative Bioarray
Creative Bioarray is dedicated to enhancing your product development success through tailored safety evaluation solutions. We prioritize milestone achievement by providing scientifically robust data and sustaining the momentum necessary for your candidate's progression. Our Safety Evaluation team develops customized strategies that address the unique requirements of each project, ensuring that your products remain on track from discovery to market.
In Vitro Toxicity
Creative Bioarray is dedicated to enhancing your product development success through tailored safety evaluation solutions. We prioritize milestone achievement by providing scientifically robust data and sustaining the momentum necessary for your candidate's progression. Our Safety Evaluation team develops customized strategies that address the unique requirements of each project, ensuring that your products remain on track from discovery to market.
Creative BioMart
Creative BioMart started from a small supplier with the development and production of recombinant protein products. After years of development and growth, we currently have over 100,000 protein products. In addition, we have also expanded a series of related products such as native proteins, cell/tissue lysates, chromatography, lectins, and detection kits. In response to customers’ needs, Creative BioMart continuously launches popular categories such as cytokines, PROTAC targets, GPCRs, labeled proteins, full length proteins, virus-related proteins, CAR-T cell targets, biomarkers, CD antigens, etc. In addition, we offer therapeutic proteins, diagnostic proteins, and GMP proteins in accordance with the demands of industrial customers.
Alfa Chemistry
Alfa Chemistry is a leading supplier and manufacturer of raw materials, fine chemicals, reagents and life science products. We are focused on providing high-quality customer service, whilst delivering the highest quality products all around the world to meet customers’ diversified needs.WebsiteFacebook
Webinar Spotlight: Bridging NK Cell Activation and Tumor Targeting
Harnessing Dual-Targeting Antibodies: A New Frontier in Cancer Immunotherapy The field of cancer immunotherapy is undergoing a seismic shift, driven by breakthroughs in antibody engineering. Among the most promising advancements are multi-engager antibodies—molecules designed to simultaneously target immune cells and tumors, creating a synergistic attack on malignancies. On May 22, 2025, researchers will unveil a groundbreaking approach in a webinar titled "Generation of a Dual-Function Multi-Engager Antibody for Simultaneous Targeting of NK Cells and Tumor Cells" (11:00 AM EDT). This event will spotlight the Targeted ADAM17 Blocker and Killer (TABK), a novel antibody complex that enhances natural killer (NK) cell activity while directing them to destroy ADAM17-expressing tumors. Webinar Spotlight: Bridging NK Cell Activation and Tumor Targeting Key Discussion Points:ADAM17's Dual Role: A protease acting as both a negative checkpoint in NK cells and a tumor-associated antigen overexpressed in cancers like melanoma and leukemia. Blocking ADAM17 boosts NK cell proliferation and cytotoxicity.TABK's Mechanism: This antibody complex combines IL-15 synergy to activate NK cells and redirects them to tumors via ADAM17 binding, effectively turning immune evasion into a therapeutic vulnerability.Preclinical Insights: Data showing enhanced tumor clearance in models where TABK bridges NK cells and cancer cells, leveraging both innate immunity and precision targeting. Registration is open for this free virtual event—an essential resource for oncologists, immunologists, and biotech professionals. The Science Behind Multi-Engager Antibodies The rise of bispecific and multispecific antibodies reflects a broader trend in oncology. These molecules overcome limitations of traditional monoclonal antibodies by:Engaging Multiple Receptors: Unlike single-target antibodies, multi-engagers bind to activating receptors (e.g., CD16a, NKG2D) on NK cells and tumor antigens, ensuring sustained immune activation.Countering Immune Evasion: By blocking inhibitory checkpoints (e.g., ADAM17) and delivering stimulatory signals (e.g., IL-15), they create a pro-inflammatory microenvironment hostile to tumors.Reducing Off-Target Effects: Precision targeting minimizes damage to healthy tissues, a critical advantage over chemotherapy and radiation.The global bispecific antibody market, projected to reach $30 billion by 2035, underscores the transformative potential of these therapies. Innovative Platforms Fueling the Antibody Revolution1. Antibody-Coupled Liposomes (ACLs)These "smart" nanoparticles use antibody-guided delivery to transport drugs directly to tumors. Examples include liposomes targeting CD74 or EZH2—proteins linked to aggressive cancers. Benefits include:Enhanced Drug Stability: Lipid bilayers protect payloads (e.g., chemotherapies, siRNA) during circulation.Tumor Microenvironment Focus: Antibodies like anti-TMEFF2 ensure localized release, reducing systemic toxicity. 2. Flow Cytometry ReagentsAdvanced kits enable real-time analysis of immune cell interactions, crucial for optimizing T-cell and NK cell therapies. Features include:Multicolor Panels: High-affinity antibodies conjugated to fluorophores track cell populations and activation states.Standardization Tools: Critical for ensuring reproducibility in CAR-T and bispecific antibody trials. 3. Modular Antibody Labeling KitsKits for fluorescent, metal, or magnetic labeling allow researchers to customize antibodies for imaging, diagnostics, or therapeutic tracking. Recent advancements prioritize:Speed: Some kits label antibodies in under 15 minutes.Site-Specificity: Techniques like glycan-targeted labeling preserve antigen-binding domains. The Road Ahead: Collaboration and Clinical TranslationThe webinar aligns with a wave of conferences in 2025 focused on bispecific antibodies, ADC therapies, and NK cell engagers. As the industry moves toward combination therapies—pairing antibodies with checkpoint inhibitors or cellular therapies—the need for robust preclinical tools and clinical-grade reagents will only grow. Join the Webinar:Date: May 22, 2025Time: 11:00 AM–12:00 PM EDTRegistration: https://www.creativebiolabs.net/generation-of-a-dual-function-multi-engager-antibody-for-simultaneous-targeting-nk-cells-and-tumor-cells.htm This is more than a webinar—it's a glimpse into the future of cancer treatment, where antibodies become architects of immune precision.
Webinar Spotlight: Bridging NK Cell Activation and Tumor Targeting
Harnessing Dual-Targeting Antibodies: A New Frontier in Cancer Immunotherapy The field of cancer immunotherapy is undergoing a seismic shift, driven by breakthroughs in antibody engineering. Among the most promising advancements are multi-engager antibodies—molecules designed to simultaneously target immune cells and tumors, creating a synergistic attack on malignancies. On May 22, 2025, researchers will unveil a groundbreaking approach in a webinar titled "Generation of a Dual-Function Multi-Engager Antibody for Simultaneous Targeting of NK Cells and Tumor Cells" (11:00 AM EDT). This event will spotlight the Targeted ADAM17 Blocker and Killer (TABK), a novel antibody complex that enhances natural killer (NK) cell activity while directing them to destroy ADAM17-expressing tumors. Webinar Spotlight: Bridging NK Cell Activation and Tumor Targeting Key Discussion Points:ADAM17's Dual Role: A protease acting as both a negative checkpoint in NK cells and a tumor-associated antigen overexpressed in cancers like melanoma and leukemia. Blocking ADAM17 boosts NK cell proliferation and cytotoxicity.TABK's Mechanism: This antibody complex combines IL-15 synergy to activate NK cells and redirects them to tumors via ADAM17 binding, effectively turning immune evasion into a therapeutic vulnerability.Preclinical Insights: Data showing enhanced tumor clearance in models where TABK bridges NK cells and cancer cells, leveraging both innate immunity and precision targeting. Registration is open for this free virtual event—an essential resource for oncologists, immunologists, and biotech professionals. The Science Behind Multi-Engager Antibodies The rise of bispecific and multispecific antibodies reflects a broader trend in oncology. These molecules overcome limitations of traditional monoclonal antibodies by:Engaging Multiple Receptors: Unlike single-target antibodies, multi-engagers bind to activating receptors (e.g., CD16a, NKG2D) on NK cells and tumor antigens, ensuring sustained immune activation.Countering Immune Evasion: By blocking inhibitory checkpoints (e.g., ADAM17) and delivering stimulatory signals (e.g., IL-15), they create a pro-inflammatory microenvironment hostile to tumors.Reducing Off-Target Effects: Precision targeting minimizes damage to healthy tissues, a critical advantage over chemotherapy and radiation.The global bispecific antibody market, projected to reach $30 billion by 2035, underscores the transformative potential of these therapies. Innovative Platforms Fueling the Antibody Revolution1. Antibody-Coupled Liposomes (ACLs)These "smart" nanoparticles use antibody-guided delivery to transport drugs directly to tumors. Examples include liposomes targeting CD74 or EZH2—proteins linked to aggressive cancers. Benefits include:Enhanced Drug Stability: Lipid bilayers protect payloads (e.g., chemotherapies, siRNA) during circulation.Tumor Microenvironment Focus: Antibodies like anti-TMEFF2 ensure localized release, reducing systemic toxicity. 2. Flow Cytometry ReagentsAdvanced kits enable real-time analysis of immune cell interactions, crucial for optimizing T-cell and NK cell therapies. Features include:Multicolor Panels: High-affinity antibodies conjugated to fluorophores track cell populations and activation states.Standardization Tools: Critical for ensuring reproducibility in CAR-T and bispecific antibody trials. 3. Modular Antibody Labeling KitsKits for fluorescent, metal, or magnetic labeling allow researchers to customize antibodies for imaging, diagnostics, or therapeutic tracking. Recent advancements prioritize:Speed: Some kits label antibodies in under 15 minutes.Site-Specificity: Techniques like glycan-targeted labeling preserve antigen-binding domains. The Road Ahead: Collaboration and Clinical TranslationThe webinar aligns with a wave of conferences in 2025 focused on bispecific antibodies, ADC therapies, and NK cell engagers. As the industry moves toward combination therapies—pairing antibodies with checkpoint inhibitors or cellular therapies—the need for robust preclinical tools and clinical-grade reagents will only grow. Join the Webinar:Date: May 22, 2025Time: 11:00 AM–12:00 PM EDTRegistration: https://www.creativebiolabs.net/generation-of-a-dual-function-multi-engager-antibody-for-simultaneous-targeting-nk-cells-and-tumor-cells.htm This is more than a webinar—it's a glimpse into the future of cancer treatment, where antibodies become architects of immune precision.
